The detection of the anesthetic and analgesic substance, frequently used recreationally, in standard drug screenings is not always a given. Common immunoassay panels utilized for initial screening in workplace or clinical settings typically do not include specific reagents designed to identify this particular compound.
Whether a testing protocol includes this substance depends heavily on the specific context, purpose, and legal requirements governing the screening. Its inclusion is more likely in situations involving suspected abuse, impaired driving investigations, or specific clinical monitoring scenarios. Historically, testing for this substance was less common but has become more prevalent with increased awareness of its misuse.